Aromatase inhibitors in the treatment of elderly women with metastatic breast cancer

Breast

Volumn 22, Issue 2, 2013, Pages 142-149

  Glück, Stefan ^a   von Minckwitz, Gunter ^b   Untch, Michael ^c  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c HELIOS KLINIKUM BERLIN BUCH   (Germany)

Author keywords

Antineoplastic agents; Aromatase inhibitors; Breast cancer; Elderly; Exemestane; Hormonal; Metastatic; Tamoxifen

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; AROMATASE INHIBITOR; BEVACIZUMAB; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; EVEROLIMUS; EXEMESTANE; FLUOROURACIL; FULVESTRANT; GEMCITABINE; LAPATINIB; LETROZOLE; MEGESTROL ACETATE; METHOTREXATE; NAVELBINE; PACLITAXEL; PROGESTERONE RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; VINCA ALKALOID;

ADL DISABILITY; AGED; ARTHRALGIA; ARTICLE; ASTHENIA; BONE DENSITY; BONE MARROW SUPPRESSION; BONE METASTASIS; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; COLORECTAL CANCER; COMORBIDITY; COUGHING; DIARRHEA; DRUG DOSE COMPARISON; DRUG FEVER; DRUG INDUCED HEADACHE; DYSPEPSIA; DYSPNEA; EDEMA; FATIGUE; FEMALE; FLUID RETENTION; FRACTURE; FRAIL ELDERLY; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GERIATRIC ASSESSMENT; GERIATRIC PATIENT; HAIR LOSS; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HEART DISEASE; HOT FLUSH; HUMAN; HYPERGLYCEMIA; HYPERTENSION; LIFE EXPECTANCY; MOTOR NEUROPATHY; MYALGIA; NAUSEA; OBESITY; OVERALL SURVIVAL; POSTMENOPAUSE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RISK ASSESSMENT; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; THROMBOEMBOLISM; VAGINA BLEEDING; VAGINA DISCHARGE; VISCERAL METASTASIS; WEIGHT GAIN;

EID: 84875509057     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2012.12.015     Document Type: Article

References (93)

1. Glass A.G., Lacey J.V., Carreon J.D., Hoover R.N. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 2007, 99:1152-1161.
2. Jemal A., Ward E., Thun M.J. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res 2007, 9:R28.
3. Altekruse S.F., Kosary C.L., Krapcho M., Neyman N., Aminoe R., Waldron W., et al. SEER cancer statistics review, 1975-2007 [Internet] 2010, National Cancer Institute, Bethesda, MD, Based on November 2009 SEER data submission, posted to the SEER web site, [cited August 25, 2011]. http://seer.cancer.gov/csr/1975_2007/.
4. Carlson R.W., Moench S., Hurria A., Balducci L., Burstein H.J., Goldstein L.J., et al. NCCN task force report: breast cancer in the older woman. J Natl Compr Canc Netw 2008, 6(Suppl. 4):S1-S25. quiz S6-S7.
5. Verkooijen H.M., Bouchardy C., Vinh-Hung V., Rapiti E., Hartman M. The incidence of breast cancer and changes in the use of hormone replacement therapy: a review of the evidence. Maturitas 2009, 64:80-85.
6. Diab S.G., Elledge R.M., Clark G.M. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 2000, 92:550-556.
7. Howlader N., Noone A.M., Krapcho M., Neyman N., Aminou R., Waldron W., et al. SEER cancer statistics review, 1975-2008 [Internet] 2011, National Cancer Institute, Bethesda, MD, Based on November 2010 SEER data submission posted to the SEER web site, [cited August 25, 2011]. http://seer.cancer.gov/csr/1975_2008/.
8. Rodriguez-Cuevas S., Macias C.G., Franceschi D., Labastida S. Breast carcinoma presents a decade earlier in Mexican women than in women in the United States or European countries. Cancer 2001, 91:863-868.
9. Freyer G., Braud A.C., Chaibi P., Spielmann M., Martin J.P., Vilela G., et al. Dealing with metastatic breast cancer in elderly women: results from a French study on a large cohort carried out by the 'Observatory on Elderly Patients'. Ann Oncol 2006, 17:211-216.
10. Aapro M.S., Kohne C.H., Cohen H.J., Extermann M. Never too old? Age should not be a barrier to enrollment in cancer clinical trials. Oncologist 2005, 10:198-204.
11. Kemeny M.M., Peterson B.L., Kornblith A.B., Muss H.B., Wheeler J., Levine E., et al. Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol 2003, 21:2268-2275.
12. Christman K., Muss H.B., Case L.D., Stanley V. Chemotherapy of metastatic breast cancer in the elderly. The Piedmont Oncology Association experience [see comment]. JAMA 1992, 268:57-62.
13. Cheung K.L., Wong A.W., Parker H., Li V.W., Winterbottom L., Morgan D.A., et al. Pathological features of primary breast cancer in the elderly based on needle core biopsies-a large series from a single centre. Crit Rev Oncol Hematol 2008, 67:263-267.
14. Karlsson E., Lindstrom L.S., Wilking U., Skoog L., Johansson U., Bergh J. Discordance in hormone receptor status in breast cancer during tumor progression. J Clin Oncol 2010, 28(Suppl. 15). Abstract 1009.
15. Amir E., Clemons M., Freedman O.C., Miller N., Coleman R., Purdie C., et al. Tissue confirmation of disease recurrence in patients with breast cancer: pooled analysis of two large prospective studies. J Clin Oncol 2010, 28(Suppl. 15). Abstract 1007.
16. Locatelli M.A., Curigliano G., Fumagalli L., Bagnardi V., Aurilio G., Della Vigna P., et al. Should liver metastases of breast cancer be biopsied to improve treatment choice?. J Clin Oncol 2010, 28(Suppl. 15). Abstract CRA1008.
17. Lindstrom L.S., Karlsson E., Wilking U., Bergh J. Discodance in hormone receptor and HER2 status in breast cancer during tumor progression. Cancer Res 2010, 70(Suppl. 2). Abstract S3-S5.
18. Bernow M., Wilking U., Bergh J., Jonsson B., Wilking N. Re-testing of HER2 status in recurring metastatic breast cancer is a clinically relevant and cost-effective strategy. Cancer Res 2010, 70(Suppl. 2). Abstract P1-09-5.
19. Gynecological oncology breast commission. Guidel Breast Cancer Treat 2011, [Internet], [cited August 31, 2011]. http://www.ago-online.de/index.php%3flang%3den%26site%3dmamma_guide_topical%26topic%3dmamma_guide.
20. Hurria A., Lichtman S.M. Pharmacokinetics of chemotherapy in the older patient. Cancer Control 2007, 14:32-43.
21. Muss H.B., Berry D.A., Cirrincione C.T., Theodoulou M., Mauer A.M., Kornblith A.B., et al. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 2009, 360:2055-2065.
22. Blum J.L., Kohles J., McKenna E., Scotto N., Hu S., Odom D., et al. Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials. Breast Cancer Res Treat 2011, 125:431-439.
23. Gelman R.S., Taylor SGt Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: the elimination of age trends in toxicity by using doses based on creatinine clearance. J Clin Oncol 1984, 2:1404-1413.
24. Bajetta E., Procopio G., Celio L., Gattinoni L., Della Torre S., Mariani L., et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005, 23:2155-2161.
25. Kris M.G., Hesketh P.J., Somerfield M.R., Feyer P., Clark-Snow R., Koeller J.M., et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006, 24:2932-2947.
26. Kris M.G., Urba S.G., Schwartzberg L.S. Clinical roundtable monograph. Treatment of chemotherapy-induced nausea and vomiting: a post-MASCC 2010 discussion. Clin Adv Hematol Oncol 2011, 9(Suppl. 1-15).
27. Roila F., Herrstedt J., Aapro M., Gralla R.J., Einhorn L.H., Ballatori E., et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010, 21(Suppl. 5):v232-v243.
28. Schonberg M.A., Marcantonio E.R., Ngo L., Li D., Silliman R.A., McCarthy E.P. Causes of death and relative survival of older women after a breast cancer diagnosis. J Clin Oncol 2011, 29:1570-1577.
29. Ewer M.S., Gluck S. A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health. Cancer 2009, 115:1813-1826.
30. Barrett-Lee P.J., Dixon J.M., Farrell C., Jones A., Leonard R., Murray N., et al. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Ann Oncol 2009, 20:816-827.
31. O'Brien M.E., Wigler N., Inbar M., Rosso R., Grischke E., Santoro A., et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004, 15:440-449.
32. Conroy S.M., Maskarinec G., Wilkens L.R., White K.K., Henderson B.E., Kolonel L.N. Obesity and breast cancer survival in ethnically diverse postmenopausal women: the Multiethnic Cohort Study. Breast Cancer Res Treat 2011, 129:565-574.
33. Chen Z., Maricic M., Bassford T.L., Pettinger M., Ritenbaugh C., Lopez A.M., et al. Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study. Arch Intern Med 2005, 165:552-558.
34. Kanis J.A., McCloskey E.V., Powles T., Paterson A.H., Ashley S., Spector T. A high incidence of vertebral fracture in women with breast cancer. Br J Cancer 1999, 79:1179-1181.
35. Hadji P., Body J.J., Aapro M.S., Brufsky A., Coleman R.E., Guise T., et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 2008, 19:1407-1416.
36. Hadji P. Guidelines for osteoprotection in breast cancer patients on an aromatase inhibitor. Breast Care (Basel) 2010, 5:290-296.
37. Body J.J., Bergmann P., Boonen S., Boutsen Y., Devogelaer J.P., Goemaere S., et al. Management of cancer treatment-induced bone loss in early breast and prostate cancer - a consensus paper of the Belgian Bone Club. Osteoporos Int 2007, 18:1439-1450.
38. Hillner B.E., Ingle J.N., Chlebowski R.T., Gralow J., Yee G.C., Janjan N.A., et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003, 21:4042-4057.
39. Van Poznak C.H., Temin S., Yee G.C., Janjan N.A., Barlow W.E., Biermann J.S., et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 2011, 29:1221-1227.
40. National Comprehensive Cancer Network NCCN clinical practice guidelines in Oncology™ v.1.2012. Breast Cancer 2012, [Internet], [cited March 9, 2012]. http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
41. Deitcher S.R., Gomes M.P. The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review. Cancer 2004, 101:439-449.
42. Hippisley-Cox J., Coupland C. Development and validation of risk prediction algorithm (QThrombosis) to estimate future risk of venous thromboembolism: prospective cohort study. BMJ 2011, 343:d4656.
43. Holmes C.E., Muss H.B. Diagnosis and treatment of breast cancer in the elderly. CA Cancer J Clin 2003, 53:227-244.
44. Schairer C., Mink P.J., Carroll L., Devesa S.S. Probabilities of death from breast cancer and other causes among female breast cancer patients. J Natl Cancer Inst 2004, 96:1311-1321.
45. Manders K., van de Poll-Franse L.V., Creemers G.J., Vreugdenhil G., van der Sangen M.J., Nieuwenhuijzen G.A., et al. Clinical management of women with metastatic breast cancer: a descriptive study according to age group. BMC Cancer 2006, 6:179.
46. Dordea M, Jones R, Pujol NA, Sar S, Batson S, Fetherston A, et al. Comparison of breast cancer management at the extremes of age - a single centre study. Presented at: 33rd Annual San Antonio Breast Cancer Symposium; December 8-12, 2010; San Antonio, TX. Abstract P3-11-14.
47. Follana P, Chamorey E, Dadone B, Gal J, Courdi A, Barriere J, et al. Prognostic factors in 337 elderly women with metastatic breast cancer. Presented at: 33rd Annual San Antonio Breast Cancer Symposium; December 8-12, 2010; San Antonio, TX. Abstract P3-10-39.
48. Rossi A., Colantuoni G., Maione P., Ferrara C., Airoma G., Barzelloni M.L., et al. Chemotherapy of breast cancer in the elderly. Curr Med Chem 2005, 12:297-310.
49. Crivellari D., Aapro M., Leonard R., von Minckwitz G., Brain E., Goldhirsch A., et al. Breast cancer in the elderly. J Clin Oncol 2007, 25:1882-1890.
50. Balducci L., Extermann M. Management of cancer in the older person: a practical approach. Oncologist 2000, 5:224-237.
51. Cardoso F., Castiglione M. Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009, 20(Suppl. 4):15-18.
52. Wildiers H., Kunkler I., Biganzoli L., Fracheboud J., Vlastos G., Bernard-Marty C., et al. Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancet Oncol 2007, 8:1101-1115.
53. Dordea M., Jones R., Nicolas A.P., Sudeshna S., Solomon J., Truran P., et al. Surgery for breast cancer in the elderly - how relevant?. Breast 2011, 20:212-214.
54. Rai S., Stotter A. Management of elderly patients with breast cancer: the time for surgery. ANZ J Surg 2005, 75:863-865.
55. Syed B.M., Johnston S.J., Wong D.W.M., Morgan D.A.L., Ellisand I.O., Cheung K.L. Surgery versus primary endocrine therapy for elderly women with estrogen receptor-positive early operable primary breast cancer: survival analysis and correlation with oestrogen receptor positivity. J Clin Oncol 2009, 27(15s). Abstract 612.
56. Vogel C.L., East D.R., Voigt W., Thomsen S. Response to tamoxifen in estrogen receptor-poor metastatic breast cancer. Cancer 1987, 60:1184-1189.
57. Kaufman B., Mackey J.R., Clemens M.R., Bapsy P.P., Vaid A., Wardley A., et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009, 27:5529-5537.
58. Johnston S., Pippen J., Pivot X., Lichinitser M., Sadeghi S., Dieras V., et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009, 27:5538-5546.
59. Cortes J., Saura C., Bellet M., Munoz-Couselo E., Ramirez-Merino N., Calvo V., et al. HER2 and hormone receptor-positive breast cancer-blocking the right target. Nat Rev Clin Oncol 2011, 8:307-311.
60. Kaufman P.A., Brufsky A.M., Mayer M., Rugo H.S., Tripathy D., Yood M.U., et al. Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study. Breast Cancer Res Treat 2012, 135:875-883.
61. Joensuu H., Ejlertsen B., Lonning P.E., Rutqvist L.E. Aromatase inhibitors in the treatment of early and advanced breast cancer. Acta Oncol 2005, 44:23-31.
62. Gibson L., Lawrence D., Dawson C., Bliss J. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev 2009, CD003370.
63. Yamnik R.L., Holz M.K. mTOR/S6K1 and MAPK/RSK signaling pathways coordinately regulate estrogen receptor alpha serine 167 phosphorylation. FEBS Lett 2010, 584:124-128.
64. Johnston S.R. Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer. Clin Cancer Res 2006, 12:1061s-1068s.
65. Schiff R., Massarweh S.A., Shou J., Bharwani L., Mohsin S.K., Osborne C.K. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 2004, 10:331S-336S.
66. Baselga J., Campone M., Piccart M., Burris H.A., Rugo H.S., Sahmoud T., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012, 366:520-529.
67. Bonneterre J., Thurlimann B., Robertson J.F., Krzakowski M., Mauriac L., Koralewski P., et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000, 18:3748-3757.
68. Vergote I., Bonneterre J., Thurlimann B., Robertson J., Krzakowski M., Mauriac L., et al. Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women. Eur J Cancer 2000, 36(Suppl. 4):S84-S85.
69. Nabholtz J.M., Buzdar A., Pollak M., Harwin W., Burton G., Mangalik A., et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000, 18:3758-3767.
70. Milla-Santos A., Milla L., Portella J., Rallo L., Pons M., Rodes E., et al. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study. Am J Clin Oncol 2003, 26:317-322.
71. Bonneterre J., Buzdar A., Nabholtz J.M., Robertson J.F., Thurlimann B., von Euler M., et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001, 92:2247-2258.
72. Nabholtz J.M. Advanced breast cancer updates on anastrozole versus tamoxifen. J Steroid Biochem Mol Biol 2003, 86:321-325.
73. Nabholtz J.M., Bonneterre J., Buzdar A., Robertson J.F., Thurlimann B. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer 2003, 39:1684-1689.
74. Buzdar A.U., Jonat W., Howell A., Jones S.E., Blomqvist C.P., Vogel C.L., et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 1998, 83:1142-1152.
75. Buzdar A.U., Jones S.E., Vogel C.L., Wolter J., Plourde P., Webster A. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group. Cancer 1997, 79:730-739.
76. Jonat W., Howell A., Blomqvist C., Eiermann W., Winblad G., Tyrrell C., et al. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 1996, 32A:404-412.
77. Gluck S. Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer. Am J Clin Oncol 2010, 33:314-319.
78. Paridaens R.J., Dirix L.Y., Beex L.V., Nooij M., Cameron D.A., Cufer T., et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 2008, 26:4883-4890.
79. Chernozemsky I, Kalinov K, Tzekov H, Racheva M, Hristova S, Tomova A, et al. Randomized phase III trial of exemestane or tamoxifen in first-line hormonal treatment of postmenopausal women with metastatic breast cancer. Presented at: 30th Annual San Antonio Breast Cancer Symposium; December 13-16, 2007; San Antonio, TX. Abstract 2102.
80. Chia S., Gradishar W., Mauriac L., Bines J., Amant F., Federico M., et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 2008, 26:1664-1670.
81. Kaufmann M., Bajetta E., Dirix L.Y., Fein L.E., Jones S.E., Zilembo N., et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 2000, 18:1399-1411.
82. Carlini P., Michelotti A., Ferretti G., Ricci S., Giannarelli D., Pellegrini M., et al. Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients. Cancer Invest 2007, 25:102-105.
83. Gennatas C., Michalaki V., Carvounis E., Psychogios J., Poulakaki N., Katsiamis G., et al. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on letrozole or anastrozole. A phase II trial conducted by the Hellenic Group of Oncology (HELGO). Tumori 2006, 92:13-17.
84. Iaffaioli R.V., Formato R., Tortoriello A., Del Prete S., Caraglia M., Pappagallo G., et al. Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer. Br J Cancer 2005, 92:1621-1625.
85. Lonning P.E., Bajetta E., Murray R., Tubiana-Hulin M., Eisenberg P.D., Mickiewicz E., et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 2000, 18:2234-2244.
86. Steele N., Zekri J., Coleman R., Leonard R., Dunn K., Bowman A., et al. Exemestane in metastatic breast cancer: effective therapy after third-generation non-steroidal aromatase inhibitor failure. Breast 2006, 15:430-436.
87. Thurlimann B., Paridaens R.J., Serin D., Bonneterre J., Roche H., Murray E., et al. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Eur J Cancer 1997, 33:1767-1773.
88. Mouridsen H., Gershanovich M., Sun Y., Perez-Carrion R., Boni C., Monnier A., et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003, 21:2101-2109.
89. Mouridsen H., Gershanovich M., Sun Y., Perez-Carrion R., Boni C., Monnier A., et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001, 19:2596-2606.
90. Mouridsen H., Chaudri-Ross H.A. Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer. Oncologist 2004, 9:497-506.
91. Buzdar A., Douma J., Davidson N., Elledge R., Morgan M., Smith R., et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001, 19:3357-3366.
92. Dombernowsky P., Smith I., Falkson G., Leonard R., Panasci L., Bellmunt J., et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998, 16:453-461.
93. Gershanovich M., Chaudri H.A., Campos D., Lurie H., Bonaventura A., Jeffrey M., et al. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). Ann Oncol 1998, 9:639-645.